Report on demographics of gall bladder cancer in Delaware and retrospective review of treatment strategies for gallbladder cancer in a large community cancer center

2016 ◽  
Vol 25 (2) ◽  
pp. 86-91 ◽  
Author(s):  
Muhammad Baig ◽  
Michael Guarino ◽  
Nicholas Petrelli
2019 ◽  
Vol 9 (1) ◽  
pp. 23-29
Author(s):  
Hasina Alam ◽  
Tanvir Ahmed ◽  
Hashim Rabbi ◽  
Md Mamunur Rashid

Background: Gall bladder cancer (GBC) is a burning topic of discussion in the recent era of laparoscopic cholecystectomy. In 1% of patients undergoing cholecystectomy for cholelithiasis, an incidental gallbladder carcinoma is discovered. Reports of laparoscopic cholecystectomies for cholelithiasis have resulted in earlier discovery of gallbladder cancer. So an increasing number of gall bladder cancer patients in earlier stage are now attending physicians and surgeons. These patients have an excellent chance of survival if aggressively and appropriately managed. Radical cholecystectomy is the only potentially curative therapy for this group of patients. It is crucial to make proper treatment decisions early, rather than after a cholecystectomy - an operation that is incomplete except for the earliest stage of the disease.Present study is a small document about the various presentations and management of gall bladder cancer. It will highlight the options available to patients in Bangladesh which is certainly in line with the internationally accepted standard treatment. Methods: This observational study included patients with confirmed gall bladder malignancy (pre-operative, intra- operative or post- operative) presenting in Hepato-Bialiary-Pancreatic Surgery unit (HBPS), of Bangladesh institute of Diabetes, Endocrine and Metabolic Disorders (BIRDEM) Hospital, in 2004-2005. The patients were diagnosed with detail history, proper clinical examinations and appropriate investigations. The disease status was staged and the patients were appropriately counselled. Patients presenting in stage Ib, II and a few stage III patients underwent loco-regional enblock resection of malignant gall bladder with regional hepatic segments (IVB & V), without violating the cystic plate, skeletonization of hepatoduodenal ligament, clearance of fascia, fat of hepatic hilum with/without excision of bile duct followed by Roux-en-Y hepatico/ cholangio- jejunostomy, where necessary. Patients in advanced stages underwent some form of palliative procedure. All were regularly followed by a standard protocol. Results: This study comprise of 20 consecutive cases of GBC. Three (15%) patients presented with histopathological report of gall bladder malignancy after cholecystectomy. Seven (35%) patients underwent curative enmass resection. Thirteen patients (65%) were offered, appropriate palliative procedure. In this study, 35% cases had a disease free survival of five years. These were the cases in stage Ib & II who underwent a curative radical resection (enmass resection or bisegmentectomy after cholecystectomy). The rest of the patients (65%) had very poor survival. They were the patients in Stage III & IV disease who underwent some sort of palliative procedure with or without chemotherapy. The mean survival in these patients was 7.2 months. Conclusion: With improvements in imaging, staging and hepatic and biliary resection, there is now hope for patients with non-metastatic gallbladder cancer. Radical surgery has been shown to be effective in properly selected patients. It is very important to carry out a proper broad scale study of these cancers in our country. A detailed study will invariably strengthen our efforts to combat this killer disease. More studies need to be done in this context to draw any inference regarding the best way of handling this gloomy condition. Birdem Med J 2019; 9(1): 23-29


2014 ◽  
Vol 3 (1) ◽  
pp. 27-30
Author(s):  
Sujit Kumar ◽  
Prakash Kafle ◽  
N Maharjan ◽  
BN Patowar ◽  
N Belbase ◽  
...  

Objective: To evaluate the clinical profile of patients with gallbladder cancer. Methodology: This is a single institution based retrospective study of patients with gallbladder cancer who presented at College of Medical Sciences and Teaching Hospital, Bharatpur, Chitwan, Nepal. Patients presenting during the two years period from August 2011 to July 2013 were reviewed. Result: Out of 12 patients, 9 were females (75%) and 3 were males (25%), showing female preponderance. Most of the patients (75%) were in age group of 51-70 years. Only one patient (8%) was below 50 years of age. Main symptom was pain associated with anorexia, nausea & vomiting. Major signs were palpable mass, hepatomegaly and jaundice. All the histopathological reports were adenocarcinoma. 8 patients (66.66%) presented with advanced disease and were managed with extended cholecystectomy followed by systemic chemotherapy. Conclusions: Prevalence of gall bladder cancer is higher in females in our series. Most of the patients were in fifth to seventh decade of life and presented in advanced stage. Gallbladder cancer showed association with gallstones. DOI: http://dx.doi.org/10.3126/jonmc.v3i1.10050 Journal of Nobel Medical College Vol.3(1) 2014; 27-30


2020 ◽  
Vol 18 (3) ◽  
pp. 547-550
Author(s):  
Rajesh Poudel ◽  
Anita Shah

Background: Gallbladder cancer is the most common biliary tract cancer. Incidence rate of gall bladder cancer varies worldwide.  Most of the patient with gall bladder cancer remained asymptomatic until late. Preoperative early diagnosis of carcinoma of gallbladder is rare, occurring in fewer than 20% of patients. Role of routine histopathology for cholecystectomy specimen is debatable. Aim of this study is to find the incidence of incidental gall bladder cancer and determine whether routine histopathology of cholecystectomy specimen is required or not. Methods: This is a retrospective descriptive study carried out in Universal College of Medical Sciences, Bhairahawha, Nepal. Histopathology reports of all patients who had undergone cholecystectomies from June 2014 to September 2018 were reviewed. Patients’ information regarding inpatient number, age, sex, year of diagnosis, preoperative diagnosis, intraoperative findings, histopathology report and pathological staging were recorded. Data were entered and analyzed using Microsoft Excel version 14. Results: Total of 418 routine cholecystectomies were performed during this period. Seven cases of incidental gall bladder cancer were diagnosed. None of the patients had preoperative suspicion for malignancy. One patient had intraoperative suspicion of lesion. Conclusions: Incidence of incidental gallbladder cancer is 1.67%. It is recommended that routine histopathology of cholecystectomy specimen should be sent for early diagnosis and improve survival of patient with gall bladder cancer. Keywords: Cholecystectomy; gall bladder cancer; incidence, routine histopathology


2020 ◽  
Vol 19 (16) ◽  
pp. 2019-2033 ◽  
Author(s):  
Pratibha Pandey ◽  
Mohammad H. Siddiqui ◽  
Anu Behari ◽  
Vinay K. Kapoor ◽  
Kumudesh Mishra ◽  
...  

Background: The aberrant alteration in Jab1 signalosome (COP9 Signalosome Complex Subunit 5) has been proven to be associated with the progression of several carcinomas. However the specific role and mechanism of action of Jab1 signalosome in carcinogenesis of gall bladder cancer (GBC) are poorly understood. Objective: The main objective of our study was to elucidate the role and mechanism of Jab1 signalosome in gall bladder cancer by employing siRNA. Methods: Jab1 overexpression was identified in gall bladder cancer tissue sample. The role of Jab1-siRNA approach in cell growth inhibition and apoptotic induction was then examined by RT-PCR, Western Blotting, MTT, ROS, Hoechst and FITC/Annexin-V staining. Results: In the current study, we have shown that overexpression of Jab1 stimulated the proliferation of GBC cells; whereas downregulation of Jab1 by using Jab1-siRNA approach resulted incell growth inhibition and apoptotic induction. Furthermore, we found that downregulation of Jab1 induces cell cycle arrest at G1 phase and upregulated the expression of p27, p53 and Bax gene. Moreover, Jab1-siRNA induces apoptosis by enhancing ROS generation and caspase-3 activation. In addition, combined treatment with Jab1-siRNA and gemicitabine demonstrated an enhanced decline in cell proliferation which further suggested increased efficacy of gemcitabine at a very lower dose (5μM) in combination with Jab1-siRNA. Conclusion: In conclusion, our study strongly suggests that targeting Jab1 signalosome could be a promising therapeutic target for the treatment of gall bladder cancer.


2019 ◽  
Vol 19 (6) ◽  
pp. 826-837 ◽  
Author(s):  
Pratibha Pandey ◽  
Preeti Bajpai ◽  
Mohammad H. Siddiqui ◽  
Uzma Sayyed ◽  
Rohit Tiwari ◽  
...  

Background:Plant sterols have proven a potent anti-proliferative and apoptosis inducing agent against several carcinomas including breast and prostate cancers. Jab1 has been reported to be involved in the progression of numerous carcinomas. However, antiproliferative effects of sterols against Jab1 in gall bladder cancer have not been explored yet.Objective:In the current study, we elucidated the mechanism of action of stigmasterol regarding apoptosis induction mediated via downregulation of Jab1 protein in human gall bladder cancer cells.Methods:In our study, we performed MTT and Trypan blue assay to assess the effect of stigmasterol on cell proliferation. In addition, RT-PCR and western blotting were performed to identify the effect of stigmasterol on Jab1 and p27 expression in human gall bladder cancer cells. We further performed cell cycle, Caspase-3, Hoechst and FITC-Annexin V analysis, to confirm the apoptosis induction in stigmasterol treated human gall bladder cancer cells.Results:Our results clearly indicated that stigmasterol has up-regulated the p27 expression and down-regulated Jab1 gene. These modulations of genes might occur via mitochondrial apoptosis signaling pathway. Caspase-3 gets activated with the apoptotic induction. Increase in apoptotic cells and DNA were confirmed through annexin V staining, Hoechst staining, and cell cycle analysis.Conclusion:Thus, these results strongly suggest that stigmasterol has the potential to be considered as an anticancerous therapeutic agent against Jab1 in gall bladder cancer.


1993 ◽  
Vol 119 (3) ◽  
pp. 165-171 ◽  
Author(s):  
Witold Zatonskí ◽  
Carlo La Vecchia ◽  
Fabio Levi ◽  
Eva Negri ◽  
Franca Lucchini

2014 ◽  
Vol 05 (03) ◽  
pp. 246-252 ◽  
Author(s):  
Mumtaz Ahmad Ansari ◽  
Satyendra K. Tiwary ◽  
Uday Pratap Shahi ◽  
Vijay K. Shukla

Tumor Biology ◽  
2015 ◽  
Vol 36 (9) ◽  
pp. 7093-7098 ◽  
Author(s):  
Ehsan Hassan Hassan ◽  
Shawkat S. Gerges ◽  
Kamal A. El-Atrebi ◽  
Hala T. El-Bassyouni

Sign in / Sign up

Export Citation Format

Share Document